20/20 Onsite, Boston, MA (2026)

02/09/2026

Enrollment stalls. Referral bottlenecks. Screen failures mounting.

If your clinical trial is facing ophthalmic assessment challenges, the warning signs are clear and the costs are climbing.

Join Jessica McKenzie, VP of Life Sciences at 20/20 Onsite, for an exclusive on-demand webinar where she reveals the field-tested framework to spot risks early, triage immediately, and protect your critical endpoints.

Watch this webinar to learn how to identify warning signals before they derail your trial timeline.

Watch the webinar now → https://hubs.ly/Q03Zxlq60

02/05/2026

Enrollment stalled. Referral pathways bottlenecked. Screen fiascos are increasing.

These aren't just operational hiccups; they're trial-ending risks that cost approximately $40K per day in direct costs, plus millions in delayed revenue.

Jessica McKenzie, VP of Life Sciences at 20/20 Onsite, has rescued dozens of derailed trials using point-of-need ophthalmic solutions that stabilize protocols and get studies back on track—fast.

Watch this exclusive webinar to see exactly how she's helped 40+ trials maintain 100% timeline compliance, even when facing critical capacity constraints.

Watch the webinar and request your free 24-hour assessment → https://hubs.ly/Q03ZxkQY0

02/04/2026

The first few days at SCOPE Summit 2026 in Orlando reinforced a theme we’re hearing everywhere across clinical operations: patient-centric trials scale faster when innovation is paired with the right partnerships.

A few takeaways that stood out:
+ Strategic innovation partnerships are now a scaling lever: Teams are looking for suppliers who can bring operational lift, not just tools or staffing.
+ Supplier selection is being modernized, but not de-humanized: Automating the intake, comparison, and contracting process matters, but so does keeping real human support in the workflow to guide decisions and unblock ex*****on.
+ Vendor governance and communication are the differentiator: The strongest teams treat vendor relationships as a performance system, not a transaction. When the partnership truly benefits sites and patients, cost becomes secondary.

If you’re at SCOPE this week (at Rosen Shingle Creek), connect with our Life Sciences Account Executive, Katie Sigg, to compare notes on patient-centric ex*****on and how to reduce site burden while protecting endpoints.

DM us to set up a time or use this link: https://hubs.ly/Q041LQV60

02/03/2026

Throughout the year, the Life Sciences team rolls with the Eye Care Team for a full day on one of our Mobile Vision Clinics, greeting patients and jumping in wherever support is needed.

This week was a clear reminder of why that matters. Our team helped support a local school visit, serving a diverse student body where over 90% of students are multilingual learners, ensuring students received high-quality care, including advanced diagnostic testing and imaging.

Proud of the team for responding quickly and staying focused on what matters most — making vision care more accessible.

02/02/2026

Distributed assessment protocols aren't about choosing between participant convenience and measurement accuracy; they're about architecting systems that deliver both.

The implementation framework requires attention to:

→ Endpoint-specific technical requirements
→ Equipment calibration standards
→ Personnel certification protocols
→ Real-time quality oversight

Remote units eliminate travel barriers while maintaining the controlled environments that ophthalmic measurements demand. Certified staff, calibrated instruments, and standardized procedures, delivered to where participants are.

The outcome is faster enrollment, stronger retention, and measurement of reliability that supports regulatory confidence.

Our framework details operational considerations for sponsors designing decentralized protocols with ophthalmic endpoints.

Access it here: https://hubs.ly/Q03Zxjjz0

01/30/2026

Distributed assessment protocols aren't about choosing between participant convenience and measurement accuracy; they're about architecting systems that deliver both.

The implementation framework requires attention to:

→ Endpoint-specific technical requirements
→ Equipment calibration standards
→ Personnel certification protocols
→ Real-time quality oversight

Remote units eliminate travel barriers while maintaining the controlled environments that ophthalmic measurements demand. Certified staff, calibrated instruments, and standardized procedures, delivered to where participants are.

The outcome is faster enrollment, stronger retention, and measurement of reliability that supports regulatory confidence.

Our framework details operational considerations for sponsors designing decentralized protocols with ophthalmic endpoints.

Access it here: https://hubs.ly/Q03_xTC10

01/29/2026

Is your SCOPE Summit schedule filling up fast? If your protocol includes ocular endpoints, save us a slot.

Katie Sigg, Account Executive, Life Sciences, will be at SCOPE Summit in Orlando, Feb 2–5, 2026, to discus about point-of-need ophthalmic assessments that reduce site burden, protect timelines, and support retention for studies with ocular endpoints.

If you’re attending, DM to set time with Katie or grab time here: https://hubs.ly/Q03_xQt20

01/27/2026

Most companies say they value iteration. Very few actually design their operations around it.

This Forbes article, by our CEO Sonali Bloom, challenges leaders to stop treating iteration as a one-off improvement cycle and start building it into decision-making, workflows, and culture.

The takeaway is simple. If iteration is not systematic, it is accidental. And accidental iteration is slow, expensive, and risky in complex environments.

Read the full article:

https://hubs.ly/Q03-Nljr0

01/26/2026

Follow Dr. Katherine Harkins, Director of Optometry at 20/20 Onsite, through a full day in Western Massachusetts. She’s traveled over two hours so participants don’t have to.

Because in clinical trials, the biggest barrier is rarely the protocol. It’s the logistics, the drive, time off work, childcare, and the reality that one missed visit window can mean missing critical endpoint data.

“These barriers to care shouldn’t be the reason you can’t participate in a clinical trial,” Katherine says.

If your study has ocular endpoints, or might, the question becomes simple: how do we bring the exam to participants, not the other way around?

Want to explore onsite eye care for clinical research?

01/24/2026

Clinical trial demographics are no longer just a compliance metric; they're a direct predictor of commercial success.

When trial populations don't reflect real-world treatment patterns, the consequences impact the bottom line:

→ 40% market reduction
→ Post-market safety signals
→ Limited payer coverage
→ Narrower label approvals

The gap isn't intentional. It's structural. Site selection favors operational convenience. Eligibility criteria filter out comorbidities. Recruitment channels reach identical patient pools.

Representative enrollment requires rethinking the operating model, not just individual protocols. Our latest analysis breaks down 6 evidence-based strategies that align trial demographics with commercial reality.

Read the full breakdown: https://hubs.ly/Q03_j0tZ0

01/23/2026

Every patient matters.

📊 The median cost per clinical trial patient is $41,117 (PubMed).
So when a participant drops out, it’s not just lost engagement - it’s lost investment.

At 20/20 Onsite, we help sponsors protect both.
By bringing care directly to patients through our mobile vision clinics, we make participation easier, improve retention, and prevent costly mid-trial losses.

When patients stay, budgets stay intact — and trials finish stronger.

Keep patients. Control your costs.

Learn more here: https://hubs.ly/Q03YXXJD0

01/22/2026

30% dropout rates in phase 3 clinical trials. The reason isn't science; it's logistics.

Watch as Albert Santiago, Regional Manager at 2020 Onsite, walks through an empty parking lot at 5:47 a.m. In just two hours, his team in Columbus will transform it into a fully operating mobile clinical imaging site.

For participants, visits can mean hours away from work, childcare coordination, and long drives. For sponsors and CROs, traditional site footprints can take months to expand and still leave entire geographies underserved.

The downstream impact is real: slower enrollment, smaller sample sizes, and communities effectively excluded from research.

When you remove geographic barriers, everything changes:
- 82% reduction in participant travel
- 70% improvement in retention rates
- Days to deploy vs. months of setup
- FDA-compliant mobile clinics with OCTs, ultra-wide field cameras, full diagnostic capability
- Clinical-grade data without geographic limits.

"Your trial isn't a building," Albert explains. "It's wherever your participants are."

What's the biggest overlooked barrier in clinical research?

20/20 Onsite

02/09/2026

02/05/2026

02/04/2026

02/03/2026

02/02/2026

01/30/2026

01/29/2026

01/27/2026

01/26/2026

01/24/2026

01/23/2026

01/22/2026

Address

Website

Alerts

Contact The Practice

Shortcuts

Share

Category